Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection

European Urology

Volumn 56, Issue 4, 2009, Pages 700-707

  Liu, Hsin Tzu ^a   Chancellor, Michael B ^b   Kuo, Hann Chorng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Detrusor injection; Nerve growth factor; Neurogenic bladder; Overactive bladder

Indexed keywords

BIOLOGICAL MARKER; BOTULINUM TOXIN A; MUSCARINIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; TOLTERODINE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DETRUSOR MUSCLE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PRIORITY JOURNAL; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BOTULINUM TOXIN TYPE A; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NEUROMUSCULAR AGENTS; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 69249216630     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.037     Document Type: Article

References (27)

1. Reitz A., Stöhrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
2. Kuo H.C. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66 (2005) 94-98
3. Popat R., Apostolidis A., Kalsi V., Gonzales G., Fowler C.J., and Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174 (2005) 984-989
4. Werner M., Schmid D.M., and Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192 (2005) 1735-1740
5. Schmid D.M., Sauermann P., Werner M., et al. Experience with 100 cases treated with botulinum-a toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 (2006) 177-185
6. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
7. Grosse J., Kramer G., and Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653-659
8. Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., and Davis J.B. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174 (2005) 977-982
9. Giannantoni A., Di Stasi S.M., Nardicchi V., et al. Botulinum A toxin injection into the detrusor decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 175 (2006) 2341-2344
10. Steers W.D., Kolbeck S., Creedon D., and Tuttle J.B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88 (1991) 1709-1715
11. Tuttle J.B., Steers W.D., Albo M., and Nataluk E. Neural input regulates tissue NGF and growth of the adult urinary bladder. J Auton Nerv Syst 49 (1994) 147-158
12. Dupont M.C., Spitsberegen J.M., Kim K.B., Tuttle J.B., and Steers W.D. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 166 (2001) 1111-1118
13. Chung Y.C., Fraser M.O., Yu Y., Chancellor M.B., de Groat W.C., and Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 165 (2001) 975-979
14. Lowe E.M., Anand P., Terenghi G., Williams-Chestnut R.E., Sinicropi D.V., and Osborne J.L. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 79 (1997) 572-577
15. Okragly A.J., Niles A.L., Saban R., et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 161 (1999) 438-441
16. Lamb K., Gebhart G.F., and Bielefeldt K. Increased nerve growth factor expression triggers bladder overactivity. J Pain 5 (2004) 150-156
17. Kim J.C., and Park E.Y. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175 (2006) 1773-1776
18. Nixon A., Colman S., Sabounjian L., et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174 (2005) 604-607
19. Patel A.K., Patterson J.M., and Chapple C.R. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50 (2006) 684-710
20. Kuo H.C. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63 (2004) 868-872
21. Steers W.D. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4 (2002) S7-S18
22. Zvara P., and Vizzard M.A. Exogenous overexpression of nerve growth factor in the urinary bladder produce bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol 7 (2007) 9
23. Bielefeldt K., Lamb K., and Gebhart G.F. Convergence of sensory pathways in the development of somatic and visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 291 (2006) G658-G665
24. Amaya F., Schimosato G., Nagano M., et al. NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. Eur J Neurosci 20 (2004) 2303-2310
25. Birder L.A., Wolf-Johnston A., Griffiths D., and Resnick N.M. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 26 (2007) 405-409
26. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
27. Chapple C., and Patel A. Botulinum toxin-new mechanisms, new therapeutic directions?. Eur Urol 49 (2006) 606-608